Ads
related to: adverum biotechnologies stock price
Search results
Results From The WOW.Com Content Network
In September 2019, Adverum announced six-month data from the first cohort of its phase I trial. [12] The stock price dropped 50% due to investor concerns over deterioration of vision that these trial subjects suffered, as well as several reports of occular inflammation. [12] In June 2020, Laurent Fischer replaced Patterson as CEO of Adverum. [13]
The option will have a per-share exercise price equal to Adverum’s closing trading price on October 16, 2024, and will vest over four years, with 25% of the underlying shares vesting on October 16, 2025, and 1/48 th of the balance of the underlying shares vesting monthly thereafter over 36 months, subject to his continued service with Adverum ...
Adverum Biotechnologies (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
REDWOOD CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today announced topline 52-week results from the LUNA Phase 2 trial, new 4-year OPTIC long-term follow-up data and key ...